Ranbaxy Pharmaceuticals, Inc. (RPI) is in a real no-name business.

The company, the US arm of Indian

generic pharmaceuticals giant Ranbaxy Laboratories Limited, makes and markets about 50 generic and
over-the-counter (OTC) drugs. It accounts for about a quarter of its parent's annual revenues. RPI's
generic offerings, produced by manufacturing subsidiary Ohm Laboratories, include anti-infectives and
treatments for cardiovascular, gastrointestinal, and central nervous system disorders. Its OTC products
include analgesics, antihistamines, and decongestants. Sister subsidiary Ranbaxy Laboratories, Inc. (RLI)
develops branded pharmaceuticals.

Ranbaxy Laboratories
From Wikipedia, the free encyclopedia
Jump to: navigation, search

Ranbaxy Laboratories Limited

Type Public

Founded 1961

Headquarters Gurgaon, Haryana, India

Employees 1100 in R&D

Website www.ranbaxy.com

Ranbaxy Laboratories Limited is India's largest pharmaceutical company. Incorporated in

1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and
manufacturing facilities in seven countries. The company went public in 1973, and Japanese
company Daiichi Sankyo gained majority control in 2008.[1]
Atul Sobti is currently Ranbaxy CEO and Managing Director,[2] having taken over from
Malvinder Singh in May 2009.[3]

Contents
[hide]
• 1 History
 ○ 1.1 Formation
○ 1.2 Trading
○ 1.3 Acquisition
• 2 See also
• 3 Notes
• 4 External links

[edit] History
[edit] Formation
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese
company Shionogi. The name Ranbaxy is a portmanteau word from the names of its first owners
Ranbir and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir
Singh and Gurbax Singh. After Bhai Mohan Singh's son Parvinder Singh joined the company in
1967, the company saw a significant transformation in its business and scale. His sons Malvinder
Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daiichi
Sankyo in June 2008.
[edit] Trading
In 1998, Ranbaxy entered the United States, the world's largest pharmaceuticals market and now
the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005.[citation needed]
For the twelve months ending on 31 December 2005, the company's global sales were at US
$1,178 million with overseas markets accounting for 75% of global sales (USA: 28%, Europe:
17%, Brazil, Russia, and China: 29%). For the twelve months ending on December 31, 2006, the
company's global sales were at US $1,300 million.
Most of Ranbaxy's products are manufactured by license from foreign pharmaceutical
developers, though a significant percentage of their products are off-patent drugs that are
manufactured and distributed without licensing from the original manufacturer because the
patents on such drugs have expired.
In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of
its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than
$10 billion.[4] In June 2008, Ranbaxy settled the patent dispute with Pfizer allowing them to sell
Atorvastatin Calcium, the generic version of Lipitor(R)and Atorvastatin Calcium-Amylodipine
Besylate, the generic version of Pfizer's Caduet(R) in the US starting November 30, 2011. The
settlement also resolved several other disputes in other countries.[citation needed]
On 23 June 2006, Ranbaxy received from the United States Food & Drug Administration a 180-
day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug at 80 mg strength.
Ranbaxy presently competes with the maker of brand-name Zocor, Merck & Co.; IVAX
Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.),
which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories, also
from India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
On 16 September 2008, the Food and Drug Administration issued two Warning Letters to
Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two
manufacturing plants in India. [5]
On 10 June 2008, Japan's Daiichi Sankyo Co. agreed to take a majority (50.1%) stake in
Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO
after the transaction. Malvinder Singh also said that this was a strategical deal and not a sell out.
[6]

On February 25, 2009 the U.S. Food and Drug Administration said it has halted reviews of all
drug applications including data developed at Ranbaxy's Paonta Sahib plant in India because of a
practice of falsified data and test results in approved and pending drug applications.
"Investigations revealed a pattern of questionable data," the FDA said. [7][8]
[edit] Acquisition
On June 11 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy,[9] for a value $2.4 billion.
In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding
Singh family in a deal worth $4.6 billion[10] by acquiring a 63.92% stake in Ranbaxy.
The addition of Ranbaxy Laboratories extends Daiichi-Sankyo's operations - already comprising
businesses in 21 countries.[citation needed] For Ranbaxy, the deal frees up its debt and imparts more
flexibility into its growth plans.[citation needed] The combined company is worth about $30 billion.[11]

Products
Acetaminophen And Codeine Phosphate Tablets - oral (100 tablets, 500 tablets) -
Codeine (Codeine Phosphate), Acetaminophen (Paracetamol)

Acetaminophen And Codeine Phosphate Tablets - oral (100 tablets, 500 tablets,
1000 tablets) - Codeine (Codeine Phosphate), Acetaminophen (Paracetamol)

Acyclovir Capsules - oral (100, 500) - Acyclovir (Aciclovir), Promethazine (Promet)

Acyclovir Tablets - oral (100, 10 x 10) - Acyclovir (Aciclovir)

Amoxicillin And Clavulanate Potassium Chewable Tablets - oral (20) Amoxicillin And
Clavulanate Potassium Tablets Chewable - oral (20) - Clavulanic Acid (Potassium
Clavulanate), Amoxicillin (Wymox)

Amoxicillin And Clavulanate Potassium For Oral Susp - oral (75 ml, 125 ml, 200 ml) -
Clavulanic Acid (Potassium Clavulanate), Amoxicillin (Wymox)

Amoxicillin And Clavulanate Potassium Oral Suspension - oral (50 ml, 75 ml, 100 ml)
- Clavulanic Acid (Potassium Clavulanate), Amoxicillin (Wymox)

Amoxicillin And Clavulanate Potassium Tablets - oral (20) - Clavulanic Acid

(Potassium Clavulanate), Amoxicillin (Wymox)

Amoxicillin And Clavulanate Potassium Tablets - oral (20, 100) - Clavulanic Acid
(Potassium Clavulanate), Amoxicillin (Wymox)

Amoxicillin Capsules Usp - oral (100, 500) - Amoxicillin (Wymox)

Amoxicillin For Oral Suspension - oral (50 ml, 75 ml, 100 ml) - Amoxicillin (Wymox)

Amoxicillin Tablets - oral (100, 500, 20) - Amoxicillin (Wymox)

Amoxicillin Tablets Chewable - oral (100, 20) Amoxicillin Tablets Chewable Usp -
oral (20) - Amoxicillin (Wymox)

Amoxicillin Tablets Chewable Usp - oral (100 tabs) Amoxicillin Tablets Usp Chewable
- oral (100 tabs, 250 tabs, 30) - Amoxicillin (Wymox)

Atenolol Tablets - oral (100 tabs, 1000 tabs) - Atenolol (Tenormin)

Benazepril Hcl And Hydrochlorothiazide Tablets - oral (100) - benazepril (Briem),

Hydrochlorothiazide (Esidrix)

Benazepril Hydrochloride Tablets - oral (90, 500, 100) - benazepril (Briem)

Bethanechol Chloride Tablets - oral (100) - Bethanechol (Duvoid)

Bethanechol Chloride Tablets - oral (100) - Bethanechol (Duvoid)

Bethanechol Chloride Tablets - oral (100) - Bethanechol (Duvoid)

Bethanechol Cholride Tablets - oral (100) - Bethanechol (Duvoid)

Buspirone Hydrochloride - oral (100, 500, 1000) Buspirone Hydrochloride Tablets -

oral (60, 180, 500) - Buspirone (Buspar)

Calcitriol Oral Solution - oral (15ml) - Calcitriol (Calcijex)

Carisoprodol Tablets - oral (100 tablets, 500 tablets, 1000 tablets) - Carisoprodol
(Soma)

Carvedilol Tablets - oral (100 tabs) - carvedilol (Coreg)

Cefaclor Capsules Usp - oral (100) - Cefaclor (Ceclor)

Cefaclor Powder For Oral Suspension Usp - oral (100 ml, 50 ml) - Cefaclor (Ceclor)

Cefaclor Powder For Oral Suspension Usp - oral (100 ml, 50 ml) - Cefaclor (Ceclor)

Cefaclor Powder For Oral Suspension Usp - oral (150 ml, 75 ml) - Cefaclor (Ceclor)

Cefaclor Powder For Oral Suspension Usp - oral (150 ml, 75 ml) - Cefaclor (Ceclor)

Cefadroxil Capsules Usp - oral (50 caps, 100 caps) Cefadroxil Tablets Usp - oral (50,
100) - Cefadroxil (Duricef)

Cefadroxil Capsules Usp - oral (50 caps, 100 caps) - Cefadroxil (Duricef)

Cefadroxil Powder For Oral Suspension - oral (75 ml, 100 ml) Cefadroxil Powder Oral
Suspension - oral (100 ml) - Cefadroxil (Duricef)

Cefazolin For Injection - intravenous, intramuscular (25 x 1, 1's) - Cefazolin (Ancef)

Cefazolin For Injection - intravenous, intramuscular (1, 10 vials) - Cefazolin (Ancef)

Cefazolin For Injection - intravenous, intramuscular (25 x 1, 1's) - Cefazolin (Ancef)

Cefazolin For Injection - intravenous, intramuscular (1, 10 vials) - Cefazolin (Ancef)

Cefpodoxime Proxetil For Oral Suspension - oral (50 ml, 75 ml, 100 ml) -
cefpodoxime proxetil (Vantin)

Cefpodoxime Proxetil Tablets - oral (20, 100) - cefpodoxime proxetil (Vantin),

Azithromycin (Zithromax)

Cefprozil For Oral Suspension - oral (50 ml, 75 ml, 100 ml) - cefprozil (Cefzil)

Cefprozil Tablets - oral (100, 500, 50) - cefprozil (Cefzil)

Cefuroxime Axetil For Oral Suspension - oral (50 ml, 100 ml) - cefuroxime axetil
(Ceftin)
Cefuroxime Axetil Tablets - oral (20, 60, 100) - Cefuroxime (Zinacef), cefuroxime
axetil (Ceftin)

Cefuroxime For Injection - intravenous, intramuscular (1, 25) - Cefuroxime (Zinacef)

Cefuroxime For Injection - intravenous (10 x 1, 1, 10)

Ciprofloxacin Tablets - oral (50, 100) - Ciprofloxacin (Cipro)

Clarithromycin For Oral Suspension - oral (50 ml, 100 ml) - Clarithromycin (Biaxin)

Clarithromycin Tablets - oral (60, 100) - Clarithromycin (Biaxin)

Clindamycin Hydrochloride Capsules - oral (100, 16) - Clindamycin (Cleocin)

Clorazepate Dipotassium Tablets - oral (100) - Clorazepate Dipotassium (Tranxene)

Dextroamphetamine Saccharate Amphetamine Asparate Dextromphetamine Sulfate

And Ampehtamine Sulfate S - oral (100) Dextroamphetamine Saccharate
Amphetamine Asparate Dextromphetamine Sulfate And Amphetamine Sulfate T -
oral (100) Dextroamphetamine Saccharate Amphetamine Aspartate
Dextroamphetamine Sulfate & Amphetamine Sulfate - oral (100) - Amphetamine
(Amfetamine), Dextroamphetamine (Dexedrine)

Dispermox Tablets For Oral Suspension - oral (20, 60) - Amoxicillin (Wymox)

Dispermox Tablets For Oral Suspension - oral (20, 60) - Amoxicillin (Wymox)

Doxycycline Capsules - oral (250, 50) - Doxycycline (Vibramycin)

Doxycycline Tablets - oral (50 tabs, 250 tabs) - Doxycycline (Vibramycin)

Enalapril Maleate Tablets - oral (100, 1000) - Enalapril

Enalapril Maleate Tablets - oral (100, 1000) - Enalapril

Etodolac Tablets - oral (100) - Etodolac (Lodine)

Felodipine Er Tablets - oral (100) - Felodipine (Agon)

Fenofibrate Tablets - oral (90, 500) Fenofirbrate Tablets - oral (90) - Procetofen (CiL)

Flecainide Acetate Tablets - oral (100) - Flecainide (Tambocor)

Fluconazole Tablets - oral (30, 100) - Fluconazole (Zonal)

Fluoxetine Capsules - oral (30, 1000, 10 bplk, 10 tablet) - Fluoxetine (Prozac)

Fluoxetine Capsules - oral (30, 90) - Fluoxetine (Prozac)

Fosinopril Sodium Hydrochlorothiazide Tablets - oral (100) - Fosinopril (Monopril),
Hydrochlorothiazide (Esidrix)

Fosinopril Sodium Tablets - oral (90, 1000) - Fosinopril (Monopril)

Furosemide Tablets - oral (500 tabs, 100 tabs) - Furosemide (Lasix)

Gabapentin Tablets - oral (100, 500) - gabapentin (Neurontin)

Ganciclovir Capsules - oral (180) - Ganciclovir (Cytovene)

Glimepiride Tablets - oral (100) - glimepiride (Amarel)

Glycopyrrolate Tablets - oral (30, 1000, 1 blister, 10) - Glycopyrrolate

(Glycopyrronium Bromide)

Hydrochlorothiazide Tablets - oral (1000 tabs) - Hydrochlorothiazide (Esidrix)

Hydrocodone Bitartrate And Acetaminophen Tablets - oral (100, 500) - Hydrocodone

(Dihydrocodeinone), Acetaminophen (Paracetamol)

Hydrocodone Bitartrate And Acetaminophen Tablets - oral (100, 500) - Hydrocodone

(Dihydrocodeinone), Acetaminophen (Paracetamol)

Hydrocodone Bitartrate And Acetaminophen Tablets - oral (100, 500) - Hydrocodone

(Dihydrocodeinone), Acetaminophen (Paracetamol)

Hydrocodone Bitartrate And Acetaminophen Tablets - oral (100, 500) - Hydrocodone

(Dihydrocodeinone), Acetaminophen (Paracetamol)

Hydroxychloroquine Sulfate Tablets - oral (100 tabs, 500 tabs) - Hydroxychloroquine

(Plaquenil)

Lisinopril Hydrochlorothiazide Tablets - oral (100) - Lisinopril (Prinivil),

Hydrochlorothiazide (Esidrix)

Lisinopril Tablets - oral (100, 1000) - Lisinopril (Prinivil)

Lorazepam Tablets - oral (100, 500, 1000) - Lorazepam (Ativan)

Metformin Hydrochloride Extended Release Tablets - oral (100)

Metformin Hydrochloride Extended Release Tablets - oral (30, 100, 500)

Metoclopramide Tablets - oral (100's, 500's) - Metoclopramide (Reglan)

Metoprolol Tartrate Tablets - oral (100, 1000) - Metoprolol (Lopressor)

Midazolam Hydrochloride Syrup - oral (118 ml) - Midazolam (Versed)

Minocycline Hydrochloride Capsules - oral (50, 500) - Minocycline (Cyclops)

Nalfon Capsules - oral (100) - Fenoprofen (Fenoprofen Calcium)

Nefazodone Hydrochloride Tablets - oral (60) - nefazodone (Serzone)

Nitrofurantoin Capsules - oral (100) - Nitrofurantoin (Macrodantin)

Nortriptyline Hydrochloride Solution Oral Usp - oral (473 ml) - Nortriptyline (Aventyl)

Ofloxacin Tablets - oral (50, 100) - Ofloxacin (Levofloxacin)

Omeprazole Delayed Release Capsules - oral (30 caps, 1000 caps, 100) -
Omeprazole (Esomeprazole)

Ondansetron Hydrochloride Tablets - oral (30) - Ondansetron (Zofran)

Oxcarbazepine Oral Suspension - oral (250 ml) - oxcarbazepine (Trileptal)

Pentazocine And Naloxone Hydrochlorides Tablets Usp - oral (100) - Pentazocine

(Talwin), Naloxone (Narcan)

Piroxicam Capsules Usp - oral (100, 500) - Piroxicam (Feldene)

Pravastatin Sodium Tablets - oral (90, 500) - Pravastatin (Pravachol)

Procto Kit - topical (1 oz) Proctosol Hcr - topical (1 oz) - Hydrocortisone (Cortisol)

Procto Kit - topical (1 oz) - Hydrocortisone (Cortisol)

Propoxyphene Hydrochloride Capsules Usp - oral (100) - Dextropropoxyphene

(Darvon)

Quinapril Hc1 And Hctz Tablets - oral (30's, 90's) - quinapril (Accupril),
Hydrochlorothiazide (Esidrix)

Raniclor Chewable Tablets - oral (20) - Cefaclor (Ceclor)

Ranitidine Syrup - oral (480 ml) - Ranitidine (Zantac)

Ranitidine Tablets - oral (30, 250, 100) - Ranitidine (Zantac)

Ranitidine Tablets - oral (7500) - Ranitidine (Zantac)

Riomet Oral Solution - oral (473 ml, 118 ml)

Seconal Sodium Capsules Usp - oral (100, 10 x 10) - Secobarbital (Sebar)

Sertraline Hydrochloride Oral Concentrate - oral (60 ml) - Sertraline (Zoloft)

Sertraline Hydrochloride Tablets - oral (30 tabs, 100 tabs, 500 tabs) - Sertraline
(Zoloft)

Simvastatin Tablets - oral (30 tabs, 50 tabs, 90 tabs, 1000 tabs) - Simvastatin
(Zocor)

Sotret Isotretinoin Capsules - oral (30, 10) - Isotretinoin (Accutane)

Sotret Isotretinoin Capsules - oral (100, 30, 10) - Isotretinoin (Accutane)

Sumatriptan Succinate - oral (1 x 5 tabs, 1 x 120 tabs, 1 blpk x 9 tabs) Sumatriptan

Succinate Tablet - oral (1 x 120 tab, 1 x 5 tab, 1 blpk x 9 tabs) - Sumatriptan
(Imigran)

Sumatriptan Succinate Tablets - oral (1 x 9 tab, 1 x 120 tab, 1 blpk x 9 tab) -

Sumatriptan (Imigran)

Tamoxifen Citrate Tablets - oral (30, 90) - Tamoxifen

Terazosin Hydrochloride Capsules - oral (100, 500) - Terazosin (Hytrin)

Verapamil Hydrochloride Sustained Release Tablets - oral (100) - Verapamil (Calan)

Zidovudine Tablets - oral (60) - Zidovudine (Retrovir)

Zolpidem Tartrate Tablets - oral (100 tabs, 500 tabs) - zolpidem (Ambien)

Zonisamide Capsules - oral (100) - zonisamide (Zonegran)

Satish Chandra Paliwal’s experience

SR.AREA SALES EXECUTIVE at

Ranbaxy laboratories ltd, LUDHIANA
Working/Currently
WORKING EXPERIENCE Working with Ranbaxy Laboratories
Ltd, (O.T.C.) Division, as a Area Sales Executive, based at
Jaipur looking after entire central region of Rajasthan 4th June
07 to 31st Dec.08,after that promoted as Sr.Area Sales Executive,
based at Ludhiana, Punjab, looking after the entire Ludhiana
region of Punjab, Since 1st Jan 09 to till date. Job
Responsibilities • Handling CFA and Distributors. • Looking
after the entire sales process of the territory. • Target
setting of the distributors. • Proper follow up of the
distributors as well as the sales team. • Co-ordination among
the sales & distribution channel.
Achievements • Handling CFA and responsibility for all
Rajasthan primaries. • Appointed one new distributor in
H.Q. town. • Two times Winner of Runner-up award of best ASE
all India. • One time winner of quarterly volini king
award. • Sales have more than doubled, as the entire focus is
on penetration, of the market & to acquire more shelf space of
the outlets. • Open seven new distributor of surrounding towns
of the territory, highest in Northern India. • Developed the
confidence of the sales & distribution channel, with regular tour
of the territory. • These small steps have helped curb the
menace of rate under-cutting, from the surrounding states.

Satish Chandra Paliwal’s education

Ranbaxy Laboratories: A challenging choice
2008 will go down as the year that Ranbaxy made its break from the past and started re-
shaping for new challenges. How does Malvinder Mohan Singh plan to take forward the
company which has been in his family for the past three generations?
In 1937, two cousins, Ranjit Singh and Gurbax Singh, set up
a company in Delhi, to distribute medicines for a Japanese
company Shionogi. The company came to be called
'Ranbaxy Laboratories'. By 1952, the company had a new
owner in Bhai Mohan Singh, who had lent his cousins money
but bought over the company when they defaulted on their
loans. Bhai Mohan Singh had left a prosperous construction
in Rawalpindi and post-Partition settled in Delhi, on the
Indian side of the border.
The fact that he was venturing into uncharted territory when he took over the
pharmaceutical distribution business from his cousins never stopped him. As grandson
Malvinder Mohan Singh, the third generation at the helm, points out, "He was an
entrepreneur and an astute businessman with strong networking skills. However, he was
clear that the basic fundamentals of operating any business were the same."
The challenges were daunting. The pharma industry in India in the 60s was dominated by
multinational companies (MNCs), no thanks to favourable laws and a complex economic
regime. Feeling the pulse of the industry, Bhai Mohan Singh argued that instead of
importing finished formulations, the company should start manufacturing locally. The
move was a success, more so, when the government soon issued new directives, stopping
the import of drugs. This turned out to be a blessing in disguise, says Malvinder, as it
enabled his grandfather to set up Ranbaxy's first (though small) manufacturing plant in
Delhi.
The next inflexion point came in the mid-60s, when Malvinder's father, Dr Parvinder
Singh, fresh from his PhD from the University of Michigan, Ann Arbor, USA, started
getting actively involved with the company. Dr Parvinder Singh started exploring off-shore
ventures but the going was tough as Ranbaxy had still to prove itself in international
markets.
Analysing his father's strategy at the time, Malvinder says, "It was essential to first prove
skill sets and competitive advantages on the home turf. To provide cost-effective drugs,
Ranbaxy started to follow a vertically integrated model. The company set up its own R&D
centres, manufacturing plants in India for bulk and dosage production and also
established a strong distribution and marketing network. After learning to compete and
lead the Indian market, the company began to utilise and transfer these experiences to
the developing and later developed markets. This learning allowed Ranbaxy to develop
distinctive capabilities and utilise its resources efficiently and effectively."
Over the next two decades, Dr Parvinder Singh kept pushing the company beyond the
nation's borders, because he clearly saw that if 99 percent of the pharma market lay
outside India, then internationalising the business was an imperative for success. His
educational background also made him see that the core of the business was the science
and one could not do without it. As Malvinder points out, "Because of his strong science
background, he also realised much ahead of time, that a sharp focus on R&D (generic and
pure innovation) was equally critical to emerge as a strong player in the global market. To
give shape to his vision, he built a strong professional management team. In the mid
90's, Dr Parvinder Singh restructured the company's international operations into four
regions and set up its first state-of-the-art R&D centre in Gurgaon, thereby announcing
the company's ambition to make the big leap in the international pharma space. Thus,
began the transformation of Ranbaxy from an India centric organisation to an MNC giant."
Educated in the West, Dr Parvinder Singh adopted the Western management style of
putting in place a team of professionals. As differences mounted between him and his
father, Bhai Mohan Singh took a back seat. As time would prove, Dr Parvinder Singh's
strategy of building up a professional management team proved crucial. On his untimely
death from cancer in 1999, D S Brar, an electrical engineer and an MBA from FMS, Delhi
who had joined the company in 1977 as a Business Development Manager and then rose
to become the President (Pharmaceuticals) in 1993, had been groomed to succeed him as
CEO and Managing Director. There was a smooth transition and Ranbaxy's expansion
plans went ahead as scheduled.
Another 'outsider' who became a key 'insider' of the Ranbaxy story was Dr Brian Tempest.
At one time regional director Far East for Glaxo, Tempest was with Ranbaxy for 14 years,
spanning 1995 to 2008. He held various roles (President, Managing Director, Chief
Executive Officer, Chief Mentor & Executive Vice Chairman and Non Executive Director).
Malvinder joined Ranbaxy in 1994 as a Management Trainee, after receiving his MBA from
Duke University's Fuqua School of Business. Dr Parvinder ensured that he went through
the grind and earned his position only after demonstrating his ability. Recalling his early
days in the company, Malvinder says, "Believing that learning is a steady and painstaking
effort, I worked my way up and over the years imbibed the business nuances in diverse
areas of operations like general management, sales and marketing, finance and business
development. I successfully drove the company's global business operations and also
played a significant role in strengthening and expanding the company's international
presence."
12 years after he joined Ranbaxy, Malvinder took as CEO and Managing Director in 2006,
 at a time when the company was facing severe sales and margin pressures. Malvinder
had to re-jig the company's business model to adapt to the changing business dynamics
of the changed patent regime and saturated markets like the US.
Looking back, Malvinder says, "Our business model was skewed towards the developed
markets and needed restructuring. We applied a fresh approach and took strategic
decisions that were out-of-the-box and unconventional at the time. We re-organised the
company, and changed the business model by balancing the company's geographic
portfolio. We focused on penetrating emerging markets which had, and continue to have,
great potential."

Ranbaxy's phenomenal growth and success can be attributed to its vertical integration, according
to Winter. That structure gives the company the ability to develop a product in the lab and
ultimately commercialize the formulation. Ranbaxy has total control over many of its products,
performing every step in the process from producing the active ingredient and manufacturing the
finished dosage form to marketing and distributing the product to pharmacies throughout the
United States.
Being vertically integrated results in an efficient and reliable process, which allows the company
to make its products available at competitive prices, Winter says.
Currently, RPI has administrative offices in Princeton, N.J.; manufacturing facilities in North
Brunswick, N.J., New Brunswick, N.J., and Gloversville, N.Y.; and sales and distribution offices
in Jacksonville. This is part of the global footprint of Ranbaxy, which serves customers in over
125 countries with ground operations in 49 markets, manufacturing operations in 11 countries
and an expanding international portfolio of affiliates, joint ventures and strategic alliances.

JACKSONVILLE, Fla. -- "Trusted Medicines for Better Lives," the phrase associated with
Ranbaxy Laboratories Ltd. (RLL), reflects the company's four decades of experience.
"Ranbaxy is one of the world's top 10 generic pharmaceutical companies, and we believe that
access to quality health care is a right, not a privilege," says vice president of trade sales Bill
Winter. "Our endeavor is to ensure the availability of quality medicines at affordable prices
across the globe. Ranbaxy is committed to work toward a healthier and happier world."
Ranbaxy Pharmaceuticals Inc. (RPI), located in Jacksonville, Fla., is a wholly owned subsidiary
of RLL and was created to help achieve its parent company's vision of becoming a research-
based international pharmaceutical company.
RLL entered the U.S. generic pharmaceuticals market in 1995, introducing its first product under
the RPI label in January 1998. Since then, RPI's generic line has experienced consistent growth
and expansion over the years. To date Ranbaxy has filed 239 abbreviated new drug applications
(ANDAs) with the U.S. Food and Drug Administration and has approval for 146 applications,
with 93 pending final approval. Today RPI remains unrelenting in this effort and has a goal of
submitting 20-plus ANDAs per year.
This fits with RPI's strategy of offering an extensive product portfolio of high-quality and
affordable generic product formulations that are readily accessible through established
distribution channels to patients and prescribers. Plans are in place to continue to add depth and
breadth to the product line to meet the needs of the U.S. health care system.
RPI's product portfolio features anti-infective agents as well as a number of compounds in a wide
variety of therapeutic areas, including cardiovascular, central nervous system, analgesia,
gastrointestinal and metabolic diseases/conditions. These generic products are manufactured as
capsules, tablets and liquids and are manufactured within cGMP facilities that are FDA-
inspected. Ultimately these products are available in the market through various chain and
independent pharmacies and other classes of trade such as wholesalers, generic distributors and
hospitals.
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical
company, is an integrated, research based, international
pharmaceutical company producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy’s continued focus on
R&D has resulted in several approvals in developed markets and significant progress in New
Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to
proprietary "platform technologies," resulting in a number of products under development. The
Company is serving its customers in over 125 countries and has an expanding international
portfolio of affiliates, joint ventures and alliances, ground operations Japan's Daiichi Sankyo has
taken complete control over India's largest pharmaceutical company Ranbaxy, a company started by Bhai
Mohan Singh, and transformed by his son Parvinder Singh. Last year, his grandsons Malvinder and Shivinder
Singh sold their entire stake in the company to Japanese pharmaceutical giant.

The Ranbaxy board has been constituted again. Malvinder Singh who was earlier working as the MD and CEO
has been removed from company board. . Atul Sobti, will shoulder the responsibility of CEO of the giant drug
maker.

Apart from this, Tsutomu Une has been elected the Chairman of the Ranbaxy board.

Balvinder Dhillon as well as Sunil Godwani will not see their names in the list of members of the Ranbaxy
board.

When contacted, Atul Sobti stated that Ranbaxy would continue to be a listed company.

He showed a strong belief that the company would be able to reverse forex losses in the subsequent quarter.
He further stated that variation in the board were to be made by the board of Ranbaxy and not by Daiichi.

Meanwhile, a Daiichi spokesperson said that the company would not forget Malvinder Singh's contribution.

Stock price of Ranbaxy went up by more than 20% today after rumour of delisting of the company shares from
stock exchanges.
 »

• Add new comment

in 49 countrie

s and manufacturing operations in 11 coun

tries.